CSC Pharma

Manufacturer: Italfarmaco

Active ingredient: Choline alfoscerate

Dosage form: solution for injection and intramuscular introduction

There are contraindications. Read the drug label and check with your physician before use.

Gliatilin (Choline alfoscerate (Alpha GPC)) increases the tolerance of neurons to ischemic stress. For patients who have suffered a brain stroke, the main strategic task is to restore the original level of social functioning. Particular attention should be given to the preservation and restoration of cognitive functions. The basis for the development of cognitive disorders is the cholinergic deficiency associated with lesions of the orbitofrontal areas, brainstem structures, limbic system and is accompanied by loss of memory, impaired memory, communication, speech, sleep. Alpha GPC gives the opportunity early to activation of the patient, to start physical therapy with him almost from the first days of the disease. Patients with a disorder of speech functions earlier begin to understand reversed speech and generate their own. Motor and cognitive functions such as memory, attention, and thinking recover much faster. Thus, the sooner use of Alpha GPC is begun, the more effective the work of the physician for the perspective of patient’s recovery after stroke and other brain injuries.

It is made from original substances – phosphate. It ensures maximum penetration of choline through the blood-brain barrier.

Russian multicenter and international studies show excellent results on the background of treatment with Gliatilin on rehabilitation of patients after stroke, head injury, with cerebrovascular diseases, cognitive disorders of various origins.

Gliatilin, unlike citicoline, has a dual mechanism of action, delivers greater amounts of choline in the brain, so its effect persists even after termination of the course of treatment.



About manufacturer

Italfarmaco, founded in 1938, stands out vividly on the background of the leading Italian pharmaceutical manufacturers with the innovative portfolio certified according to GMP and FDA standards. More than 2.2 thousand employees of Italfarmaco SpA provide the highest quality of customer service in Italy, Russia, Switzerland, Spain, Portugal, Greece, Turkey, Chile, Peru, Morocco, the USA and Brazil. In 2015, the company EFFIK International became a part of the group of companies of Italfarmaco SpA. Activities of Italfarmaco SpA with the headquarters in Milan aimed at solving significant social challenges in the cardiovascular, immuno-oncological, gynecological, dermatological, orthopedic and neurological areas of medicine. The Russian division of Italfarmaco exists since 1999 and has focused on promoting gynecological and endocrinology portfolio of Italfarmaco SpA for women’s health, assisted reproductive technologies and solutions to the problems of osteoporosis. Innovative products, ethical business and professional team characterizes the Russian division of Italfarmaco.